Aspirin and colorectal cancer: The promise of precision chemoprevention

Nature Reviews Cancer

Volumn 16, Issue 3, 2016, Pages 173-186

  Drew, David A ^a   Cao, Yin ^a,b   Chan, Andrew T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ABDOMINAL PAIN; BRAIN HEMORRHAGE; CANCER CELL; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CATABOLISM; COLORECTAL CANCER; DRUG MECHANISM; DYSPEPSIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC ASSOCIATION; GENOTYPE; GERMLINE MUTATION; HUMAN; IMMUNE RESPONSE; META ANALYSIS; MISMATCH REPAIR; NAUSEA AND VOMITING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; CHEMOPROPHYLAXIS; COLORECTAL NEOPLASMS; PATHOLOGY;

ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; HUMANS; PRECISION MEDICINE;

EID: 84959516180     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.4     Document Type: Review

References (165)

1. Siegel, R. L., Miller, K. D., & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015
2. Chan, A. T., et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila.) 5, 164-178 (2012
3. Thorat, M. A., & Cuzick, J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur. J. Epidemiol. 30, 5-18 (2015
4. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 146, 361-364 (2007
5. U.S. Preventive Services Task Force. Draft Recommendation Statement: Aspirin to prevent cardiovascular disease and cancer U.S. Preventive Services Task Force [online] http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/aspirin-To-prevent-cardiovascular-disease-And-cancer (2015
6. Chubak, J., Kamineni, A., Buist, D. S. M., Anderson, M. L., & Whitlock, E. P. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force (Agency for Healthcare Research and Quality (US), 2015
7. Dehmer, S. P., Maciosek, M. V., & Flottemesch, T. J. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Technical Report (Agency for Healthcare Research and Quality (US), 2015
8. Cuzick, J., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501-507 (2009
9. Flossmann, E., et al. Effect of aspirin on long-Term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603-1613 (2007
10. Rothwell, P. M., et al. Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612 (2012
11. Thun, M. J., Jacobs, E. J., & Patrono, C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9, 259-267 (2012
12. Nan, H., et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313, 1133-1142 (2015
13. Friis, S., Riis, A. H., Erichsen, R., Baron, J. A., & Sorensen, H. T. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann. Intern. Med. 163, 347-355 (2015
14. Rothwell, P. M., et al. Long-Term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow up of five randomised trials. Lancet 376, 1741-1750 (2010
15. Sturmer, T., et al. Aspirin use and colorectal cancer: post-Trial follow up data from the Physicians' Health Study. Ann. Intern. Med. 128, 713-720 (1998
16. Cook, N. R., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47-55 (2005
17. Burn, J., et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med. 359, 2567-2578 (2008
18. Cook, N. R., Lee, I. M., Zhang, S. M., Moorthy, M. V., & Buring, J. E. Alternate-day, low-dose aspirin and cancer risk: long-Term observational follow up of a randomized trial. Ann. Intern. Med. 159, 77-85 (2013
19. Burn, J., et al. Long-Term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet 378, 2081-2087 (2011
20. Cunningham, J. M., et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am. J. Hum. Genet. 69, 780-790 (2001
21. Fearon, E. R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479-507 (2011
22. Eide, T. J. Natural history of adenomas. World J. Surg. 15, 3-6 (1991
23. Fearon, E. R., & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990
24. Morson, B. C. The evolution of colorectal carcinoma. Clin. Radiol. 35, 425-431 (1984
25. Neugut, A. I., Johnsen, C. M., Forde, K. A., & Treat, M. R. Recurrence rates for colorectal polyps. Cancer 55, 1586-1589 (1985
26. Baron, J. A., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003
27. Sandler, R. S., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890 (2003
28. Logan, R. F., et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134, 29-38 (2008
29. Benamouzig, R., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125, 328-336 (2003
30. Ishikawa, H., et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 63, 1755-1759 (2014
31. Drew, D. A., et al. Colorectal polyp prevention by daily aspirin use is abrogated among active smokers. Cancer Causes Control 27, 93-103 (2015
32. Pommergaard, H. C., Burcharth, J., Rosenberg, J., & Raskov, H. Aspirin, calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial. Gastroenterology 150, 114-122 (2015
33. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00501059 (2015
34. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00565708 (2015
35. ISRCTN Registry. Aspirin in reducing events in the elderly. ISRCTN.org http://dx.doi.org/10.1186/ISRCTN83772183 (2015
36. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02394769 (2015
37. ISRCTN Registry. Finding the best dose of aspirin to prevent Lynch Syndrome cancers. ISRCTN.org http://dx.doi.org/10.1186/ISRCTN16261285 (2015
38. ISRCTN Registry. The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp prevention trial. ISRCTN.org http://dx.doi.org/10.1186/ISRCTN05926847 (2015
39. Whitlock, E. P., Williams, S.B., Burda, B. U., Feightner, A., & Beil, T. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U. S. Preventive Services Task Force. (Agency for Healthcare Research and Quality (US), 2015
40. Lanas, A., Wu, P., Medin, J., & Mills, E. J. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-Analysis. Clin. Gastroenterol. Hepatol. 9, 762-768 (2011
41. Serebruany, V. L., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192, 036 patients enrolled in 31 randomized controlled trials. Am. J. Cardiol. 95, 1218-1222 (2005
42. Derry, S., & Loke, Y. K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-Analysis. BMJ 321, 1183-1187 (2000
43. McQuaid, K. R., & Laine, L. Systematic review and meta-Analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624-638 (2006
44. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg versus 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 325, 1261-1266 (1991
45. Farrell, B., Godwin, J., Richards, S., & Warlow, C. The United Kingdom transient ischaemic attack (UK TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry 54, 1044-1054 (1991
46. Roderick, P. J., Wilkes, H. C., & Meade, T. W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br. J. Clin. Pharmacol. 35, 219-226 (1993
47. Weil, J., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310, 827-830 (1995
48. Ulrich, C. M., Bigler, J., & Potter, J. D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer 6, 130-140 (2006
49. Barry, E. L., et al. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. Cancer Causes Control 24, 47-54 (2013
50. Chan, A. T., Hsu, M., Zauber, A. G., Hawk, E. T., & Bertagnolli, M. M. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev. Res. (Phila.) 5, 61-72 (2012
51. Chan, A. T., et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136, 2127-2136 (2009
52. McGreavey, L. E., et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPAR? act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet. Genom. 15, 713-721 (2005
53. Roy, H. K., et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut http://dx.doi.org/10.1136/gutjnl-2015-309996 (2015
54. Thomas, S. S., et al. Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial. BMC Med. Genet. 16, 18 (2015
55. Thompson, C. L., et al. No association between cyclooxygenase 2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J. Gastroenterol. 15, 2240-2244 (2009
56. Angstadt, A. Y., et al. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene-environment interactions. Genes Chromosomes Cancer 53, 454-466 (2014
57. Scherer, D., et al. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry. Genes Chromosomes Cancer 53, 568-578 (2014
58. Garcia-Albeniz, X., & Chan, A. T. Aspirin for the prevention of colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 25, 461-472 (2011
59. Hull, M. A. Cyclooxygenase 2: how good is it as a target for cancer chemoprevention? Eur. J. Cancer 41, 1854-1863 (2005
60. Patrignani, P., & Patrono, C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim. Biophys. Acta 1851, 422-432 (2015
61. Ranger, G. S. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 34, 6277-6282 (2014
62. Schror, K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-Aspirin NSAIDs in colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 25, 473-484 (2011
63. Wang, D., & Dubois, R. N. The role of COX 2 in intestinal inflammation and colorectal cancer. Oncogene 29, 781-788 (2010
64. Dixon, D. A., Blanco, F. F., Bruno, A., & Patrignani, P. Mechanistic aspects of COX 2 expression in colorectal neoplasia. Recent Results Cancer Res. 191, 7-37 (2013
65. Fink, S. P., et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15 hydroxyprostaglandin dehydrogenase (HPGD). Sci. Transl Med. 6, 233re2 (2014
66. Chan, A. T., Ogino, S., & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX 2. N. Engl. J. Med. 356, 2131-2142 (2007
67. Elzagheid, A., et al. High cyclooxygenase 2 expression is associated with advanced stages in colorectal cancer. Anticancer Res. 33, 3137-3143 (2013
68. Pugh, S., & Thomas, G A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35, 675-678 (1994
69. Chulada, P. C., et al. Genetic disruption of Ptgs 1, as well as Ptgs 2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60, 4705-4708 (2000
70. Mutoh, M., et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res. 62, 28-32 (2002
71. Oshima, M., et al. Suppression of intestinal polyposis in Apcδ716 knockout mice by inhibition of cyclooxygenase 2 (COX 2). Cell 87, 803-809 (1996
72. Sonoshita, M., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apcδ716 knockout mice. Nat. Med. 7, 1048-1051 (2001
73. Watanabe, K., et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59, 5093-5096 (1999
74. Nishihara, R., et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 309, 2563-2571 (2013
75. IJspeert, J. E., Vermeulen, L., Meijer, G. A., & Dekker, E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat. Rev. Gastroenterol. Hepatol. 12, 401-409 (2015
76. Kedrin, D., & Gala, M. K. Genetics of the serrated pathway to colorectal cancer. Clin. Transl Gastroenterol. 6, e84 (2015
77. Bettington, M., et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62, 367-386 (2013
78. Myung, S. J., et al. 15 Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl Acad. Sci. USA 103, 12098-12102 (2006
79. Yan, M., et al. 15 Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl Acad. Sci. USA 106, 9409-9413 (2009
80. Guda, K., et al. Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev. Res. (Phila.) 7, 805-812 (2014
81. Murphey, L. J., et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 334, 266-275 (2004
82. Wang, D., & DuBois, R. N. Urinary PGE M: a promising cancer biomarker. Cancer Prev. Res. (Phila.) 6, 507-510 (2013
83. Cai, Q., et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J. Clin. Oncol. 24, 5010-5016 (2006
84. Shrubsole, M. J., et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev. Res. (Phila.) 5, 336-342 (2012
85. Johnson, J. C., et al. Urine PGE M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 4, 1358-1365 (2006
86. Bezawada, N., et al. Urinary PGE M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev. Res. (Phila.) 7, 758-765 (2014
87. Fedirko, V., et al. Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). Cancer Prev. Res. (Phila.) 8, 1061-1068 (2015
88. Wang, D., & Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer 10, 181-193 (2010
89. Bigler, J., et al. Polymorphisms predicted to alter function in prostaglandin E2 synthase and prostaglandin E2 receptors. Pharmacogenet. Genom. 17, 221-227 (2007
90. Liu, W., Poole, E. M., Ulrich, C. M., & Kulmacz, R. J. Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase 1. Pharmacogenet. Genom. 22, 525-537 (2012
91. Hubner, R. A., et al. Polymorphisms in PTGS1, PTGS2 and IL 10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. Int. J. Cancer 121, 2001-2004 (2007
92. Barry, E. L., et al. Cyclooxygenase 2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 18, 2726-2733 (2009
93. Poole, E. M., et al. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 19, 547-557 (2010
94. Resler, A. J., et al. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis 35, 2121-2126 (2014
95. Fresno Vara, J. A., et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193-204 (2004
96. Liao, X., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367, 1596-1606 (2012
97. Prage, E. B., et al. Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1. Biochemistry 50, 7684-7693 (2011
98. Morgenstern, R., Zhang, J., & Johansson, K. Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab. Rev. 43, 300-306 (2011
99. Nakanishi, M., Gokhale, V., Meuillet, E J., & Rosenberg, D. W. mPGES 1 as a target for cancer suppression: a comprehensive invited review Phospholipase A2 and lipid mediators. Biochimie 92, 660-664 (2010
100. Kwon, Y. J., et al. Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J. Thorac. Oncol. 7, 20-33 (2012
101. Aoyama, M., et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res. 65, 4587-4597 (2005
102. MacDonald, B. T., Tamai, K., & He, X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26 (2009
103. Bos, C L., et al. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25, 6447-6456 (2006
104. Gala, M. K., & Chan, A. T. Molecular pathways: aspirin and Wnt signaling-A molecularly targeted approach to cancer prevention and treatment. Clin. Cancer Res. 21, 1543-1548 (2015
105. Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., & Gutkind, J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs axin-β-catenin signaling axis. Science 310, 1504-1510 (2005
106. Goessling, W., et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136-1147 (2009
107. He, T. C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335-345 (1999
108. Gupta, R. A., et al. Prostacyclin-mediated activation of peroxisome proliferator-Activated receptor delta in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275-13280 (2000
109. Gupta, R. A., et al. Activation of nuclear hormone receptor peroxisome proliferator-Activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10, 245-247 (2004
110. Wang, D., et al Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-Activated receptor δ. Cancer Cell 6, 285-295 (2004
111. Ouyang, N., Williams, J. L., & Rigas, B. NO donating aspirin isomers downregulate peroxisome proliferator-Activated receptor (PPAR)δ expression in APCmin/+ mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis. Carcinogenesis 27, 232-239 (2006
112. Tomlinson, I., et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39, 984-988 (2007
113. Zanke, B. W., et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989-994 (2007
114. Pomerantz, M. M., et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 41, 882-884 (2009
115. Nan, H., et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J. Natl Cancer Inst. 105, 1852-1861 (2013
116. Haiman, C. A., et al. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39, 954-956 (2007
117. Montrose, D. C., et al. The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat. 116-117, 26-36 (2015
118. Ma, X., Aoki, T., Tsuruyama, T., & Narumiya, S. Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res. 75, 2822-2832 (2015
119. Chan, A. T., Ogino, S., Giovannucci, E. L., & Fuchs, C. S. Inflammatory markers are associated with risk of colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology 140, 799-808 (2011
120. Song, M., et al. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br. J. Cancer 108, 1891-1898 (2013
121. Heikkila, K., et al. Associations of circulating C reactive protein and interleukin 6 with cancer risk: findings from two prospective cohorts and a meta-Analysis. Cancer Causes Control 20, 15-26 (2009
122. Kakourou, A., et al. Interleukin 6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-Analysis of prospective studies. Cancer Causes Control 26, 1449-1460 (2015
123. Wang, X., Baek, S. J., & Eling, T. E. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG 1/GDF15) in cancer. Biochem. Pharmacol. 85, 597-606 (2013
124. Breit, S. N., et al. The TGF-β superfamily cytokine, MIC 1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29, 187-195 (2011
125. Mehta, R. S., et al. A prospective study of macrophage inhibitory cytokine 1 (MIC 1/GDF15) and risk of colorectal cancer. J. Natl Cancer Inst. 106, dju016 (2014
126. Smyth, E., Grosser, T., & FitzGerald, G. Goodman & Gillman's The Pharmacological Basis of Therapeutics (McGraw-Hill, 2011
127. Dixon, D. A., et al. Expression of COX 2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J. Clin. Invest. 116, 2727-2738 (2006
128. Chan, A. T., Ogino, S., & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649-658 (2009
129. Din, F. V., et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59, 1670-1679 (2010
130. Goh, C. H., et al. Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res. 34, 7407-7414 (2014
131. Li, P., et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-Analysis. Gut 64, 1419-1425 (2015
132. Ng, K., et al. Aspirin and COX 2 inhibitor use in patients with stage III colon cancer. J. Natl Cancer Inst. 107, 345 (2015
133. Thun, M. J., Namboodiri, M. M., & Heath, C. W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593-1596 (1991
134. Algra, A. M., & Rothwell, P. M. Effects of regular aspirin on long-Term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518-527 (2012
135. Rothwell, P. M., et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012
136. Tougeron, D., Sha, D., Manthravadi, S., & Sinicrope, F. A. Aspirin and colorectal cancer: back to the future. Clin. Cancer Res. 20, 1087-1094 (2014
137. Domingo, E., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31, 4297-4305 (2013
138. Reimers, M. S., et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern. Med. 174, 732-739 (2014
139. Kothari, N., et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 54, 487-492 (2015
140. Ye, X. F., Wang, J., Shi, W. T., & He, J. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-Analysis of observational studies. Br. J. Cancer 111, 2172-2179 (2014
141. ISRCTN Registry. ADD-ASPIRIN: the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ISRCTN.org http://dx.doi.org/10.1186/ISRCTN74358648 (2015
142. Roy, H. K., et al. Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res. 69, 4476-4483 (2009
143. Radosevich, A. J., et al. Rectal optical markers for in vivo risk stratification of premalignant colorectal lesions. Clin. Cancer Res. 21, 4347-4355 (2015
144. Liesenfeld, D. B., et al. Aspirin reduces plasma concentrations of the oncometabolite 2 hydroxyglutarate: results of a randomized, double-blind, crossover trial. Cancer Epidemiol. Biomarkers Prev. 25, 180-187 (2015
145. Gerner, E. W., & Meyskens, F. L. Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin. Cancer Res. 15, 758-761 (2009
146. Casero, R. A. Jr. & Marton, L. J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 6, 373-390 (2007
147. Gerner, E. W., & Meyskens, F. L. Jr. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4, 781-792 (2004
148. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00983580 (2015
149. Meyskens, F. L. Jr, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. (Phila.) 1, 32-38 (2008
150. Martinez, M. E., et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl Acad. Sci. USA 100, 7859-7864 (2003
151. Barry, E. L., et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J. Natl Cancer Inst. 98, 1494-1500 (2006
152. Hubner, R. A., et al. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin. Cancer Res. 14, 2303-2309 (2008
153. Zell, J. A., et al. Ornithine decarboxylase 1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J. Natl Cancer Inst. 102, 1513-1516 (2010
154. Barry, E. L., Mott, L. A., Sandler, R. S., Ahnen, D. J., & Baron, J. A. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention. Cancer Prev. Res. (Phila.) 4, 2072-2082 (2011
155. Wender, R. C. Aspirin and NSAID chemoprevention, gene-environment interactions, and risk of colorectal cancer. JAMA 313, 1111-1112 (2015
156. Hull, M. A., et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials 14, 237 (2013
157. Baron, J. A., et al. Gastrointestinal adverse effects of short-Term aspirin use: a meta-Analysis of published randomized controlled trials. Drugs R D 13, 9-16 (2013
158. Abraham, N. S., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol. 105, 2533-2549 (2010
159. Fuster, V., & Sweeny, J. M. Aspirin: a historical and contemporary therapeutic overview. Circulation 123, 768-778 (2011
160. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235 (1971
161. Kune, G. A., Kune, S., & Watson, L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48, 4399-4404 (1988
162. Vogelstein, B., et al. Genetic alterations during colorectal-Tumor development. N. Engl. J. Med. 319, 525-532 (1988
163. Giovannucci, E., et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121, 241-246 (1994
164. Giovannucci, E., et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333, 609-614 (1995
165. Cole, B. F., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-Analysis of the randomized trials. J. Natl Cancer Inst. 101, 256-266 (2009